Article

Overexpression of CCL20 and its receptor CCR6 predicts poor clinical prognosis in human gliomas.

Department of Neurosurgery, Tangdu Hospital, No. 569, Xinsi Road, Baqiao District, Xi'an City, 710038, China.
Medical Oncology (Impact Factor: 2.06). 08/2012; 29(5). DOI: 10.1007/s12032-012-0314-9
Source: PubMed

ABSTRACT Recent studies have demonstrated that the chemokine CCL20 and its receptor CCR6 may be involved in tumorigenesis, tumor progression and metastatic spread of various human malignancies. The aim of this study was to investigate the clinicopathological significance and prognostic value of CCL20 and CCR6 expression in human malignant glioma. CCL20 and CCR6 expression in human gliomas and nonneoplastic brain tissues was measured by immunohistochemistry. The association of CCL20 and CCR6 expression with clinicopathological factors or prognosis in glioma patients was statistically analyzed. The expression levels of CCL20 and CCR6 proteins were both up-regulated in glioma tissues. There was a significantly positive correlation between the expression of the two markers (r = 0.88; P < 0.001). In addition, the overexpressions of CCL20 and CCR6 were both detected in high-grade glioma tissues compared with those in low-grade tissues and increased with ascending tumor World Health Organization (WHO) grades (P = 0.006 and 0.008, respectively). The increased expressions of CCL20 and CCR6 proteins were also significantly correlated with low Karnofsky performance score (both P = 0.01). Moreover, univariate analysis found that CCL20 expression (P = 0.002), CCR6 expression (P = 0.002) and CCL20/CCR6 co-expression (P < 0.001) were all significantly associated with poor prognosis. In particular, glioma patients with CCL20/CCR6 co-expression have the shortest overall survival. Multivariate analysis further identified the expression levels of CCL20 and CCR6 to be independent prognostic factors. Our data suggest for the first time that CCL20 and CCR6 might play an important role in the regulation of aggressiveness in human gliomas. The up-regulation of CCL20 and CCR6 might be closely associated with poor clinical outcome of patients with gliomas.

0 Followers
 · 
115 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: We show here that microRNA (miR)-150 is significantly downregulated in advanced cutaneous T-cell lymphoma (CTCL), and that this downregulation is strongly associated with tumor invasion/metastasis. Inoculation of CTCL cell lines into NOD/Shi-scid IL-2γnul mice led to CTCL cell migration to multiple organs; however, prior transfection of the cells with miR-150 substantially reduced the invasion/metastasis by directly downregulating CCR6, a specific receptor for the chemokine CCL20. We also found that IL-22 and its specific receptor subunit, IL22RA1, were aberrantly overexpressed in advanced CTCL, and that production of IL-22 and CCL20 was increased in cultured CTCL cells. IL22RA1 knockdown specifically reduced CCL20 production in CTCL cells, suggesting IL-22 upregulation may activate production of CCL20 and its binding to CCR6, thereby enhancing the multidirectional migration potential of CTCL cells. CTCL cells also exhibited nutrition- and CCL20-dependent chemotaxis, which were inhibited by miR-150 transfection or CCR6 knockdown. From these findings we conclude that, in the presence of continuous CCR6 upregulation accompanied by miR-150 downregulation, IL-22 activation leads to continuous CCL20-CCR6 interaction in CTCL cells and, in turn, autocrine metastasis to distal organs. This suggests miR-150, CCL20, and CCR6 could be key targets for the treatment of advanced CTCL.
    Blood 01/2014; 123(10). DOI:10.1182/blood-2013-09-527739 · 9.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The CCL20 chemokine has potent antitumor activities through chemoattracting immature dentritic cells. But the maturation status of tumoral dentritic cells are important limiting factors in DC-based immunity. The endogenous availability of IL-15 was effective in inducing the dentritic cells maturation and IL-15 also shows tumor-specific antitumor activities. We constructed a CCL20/IL-15 bicistronic adenovirus (Ad-CCL20-IL-15) and confirmed its combined antitumor effect in vitro and in vivo. Intratumoral injection of Ad-CCL20-IL-15 into both CT-26 and B16F10 cells resulted in marked reduction of tumor growth in our model. Splenocytes treated by Ad-CCL20-IL-15 developed tumor-specific cytotoxic T cells and IFN-γ secretion could protect mice from rechallenging. This study suggests that CCL20/IL-15 can induce a strong antitumor immune response in tumor tissues and it is a suitable candidate for cancer immunotherapy.
    Immunobiology 06/2014; DOI:10.1016/j.imbio.2014.02.009 · 3.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Recent studies have demonstrated that the CC chemokine receptor 6 (CCR6) may be involved in tumorigenesis and tumor progression of various human malignancies. The aim of this study was to investigate the clinical significance and prognostic value of CCR6 expression in human hepatocellular carcinoma (HCC).MethodsCCR6 protein levels were evaluated by Western blot in samples from 25 HCC and matched adjacent noncancerous liver tissues. CCR6 protein expression levels were also examined by immunohistochemistry in association with clinicopathologic features and prognosis in 212 HCC patients. The effects of CCR6 on HCC cell proliferation and invasion were examined in vitro.ResultsWestern blot analysis showed significantly higher CCR6 protein in HCC than that in matched adjacent noncancerous liver tissues. By immunohistochemistry, CCR6 expression correlated with multicentricity (P = 0.014) and vascular invasion (P = 0.009). Importantly, CCR6 expression was an independent prognostic factor for the overall survival of HCC patients [hazard ratio = 3.07, 95% confidence interval (CI) = 1.94–4.76, P = 0.013]. In vitro data revealed that CCR6 promoting HCC cell proliferation through regulating p21, p27, and cyclin D1.ConclusionsCCR6 could be used as a molecular marker to predict prognosis for HCC. J. Surg. Oncol. © 2014 Wiley Periodicals, Inc.
    Journal of Surgical Oncology 08/2014; 110(2). DOI:10.1002/jso.23598 · 2.84 Impact Factor